David S. Sanders is a partner and business lawyer with Foley & Lardner LLP and serves as the managing partner of the firm’s Washington, D.C. office. He is also the vice-chair of the firm’s Business Law Department and co-chair of the Trade Secret/Noncompete Specialty Practice. From 2010 through 2017, David served as co-chair of the firm’s Transactional & Securities Practice. David's practice is concentrated on mergers and acquisitions, joint ventures, employment, non-compete and trade secret issues, executive employment and termination agreements, leases, license agreements, general corporate matters and the drafting and negotiation of all types of contracts and corporate documents. He is a member of the firm's Commercial Transactions & Business Counseling, Private Equity & Venture Capital and Real Estate Practices, as well as the Sports, Medical Devices, Technology and Health Care Industry Teams. He also serves on the firm's Diversity Committee and Recruiting Committee.
David counsels public and private corporations and other business entities, including corporations and limited liability companies, on corporate matters involving formation, operation, and growth, as well as employment matters. David negotiates merger and acquisition transactions, joint ventures and other business contracts, leases, and agreements on behalf of clients. He frequently assists clients in negotiating, drafting, and creating various operational documents, including stock purchase, asset purchase and merger documents, employment and non-compete agreements, licensing, strategic alliance and joint venture agreements, employee termination agreements, confidentiality and non-disclosure agreements, stock option plans and leases. His general representation of business enterprises includes corporations, limited liability companies and partnerships. He is experienced in general corporate matters, including incorporation, organization, operating agreements and shareholders’ agreements.
A substantial portion of David's practice involves representing medical devices, health services and biopharmaceutical companies, including with respect to mergers and acquisitions, joint ventures and manufacturing, purchasing, distribution and supply agreements.
